<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154589">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01744691</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1117-CA</org_study_id>
    <secondary_id>2012-004476-19</secondary_id>
    <nct_id>NCT01744691</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion</brief_title>
  <official_title>An Open-label, Single Arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma With 17p Deletion (RESONATE™-17)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Belgium: Federal Agency for Medicinal Products and Health Products</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>New Zealand: Ministry of Health</authority>
    <authority>Turkey:  Clinical Drug Research Department (Klinik Ilaç Arsatirmalari Sube Mudurlugu) (MHDP)</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-label, Single arm, Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase
      Inhibitor PCI-32765 (Ibrutinib) in Patients with Relapsed or Refractory Chronic Lymphocytic
      Leukemia or Small Lymphocytic Lymphoma with 17p Deletion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, international, open-label, single arm, Phase 2 study designed to
      evaluate the efficacy and safety of PCI-32765 in subjects with relapsed/refractory CLL or
      SLL with del 17p. All subjects will receive PCI-32765 until disease progression or
      unacceptable toxicity occurs.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>6 -12  months after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>18 months after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Parameters: Number and type of adverse events</measure>
    <time_frame>18 months after last patient enrolled</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>18 months after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Overall survival</measure>
    <time_frame>18 months after last patient enrolled</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">111</enrollment>
  <condition>Chronic Lymphocytic Leukemia With 17p Deletion</condition>
  <condition>Small Lymphocytic Lymphoma With 17p Deletion</condition>
  <arm_group>
    <arm_group_label>PCI-32765</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive PCI-32765 420 mg (3 x 140-mg capsules) orally once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCI-32765</intervention_name>
    <description>All subjects will receive PCI-32765 420 mg (3 x 140-mg capsules) orally once daily.</description>
    <arm_group_label>PCI-32765</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Documentation of del (17p13.1)

          -  Must have relapsed or refractory CLL/SLL after receiving at least 1 prior line of
             systemic therapy.

          -  Measurable nodal disease by computed tomography (CT)

        Key Exclusion Criteria:

          -  History or current evidence of Richter's transformation or prolymphocytic leukemia

          -  Prior hematologic stem cell transplantation &lt;6 months from study enrollment or any
             ongoing GVHD

          -  Prior exposure to PCI-32765
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alvina Chu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pharmacyclics.com</url>
    <description>www.pharmacyclics.com</description>
  </link>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 7, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
